Table 2.
Drug | Number of trials registered as of 19th August, 2020 | Aspects being explored |
---|---|---|
Hydroxychloroquine | 229 | Use of this drug alone or in combination of other agents, or compared to other agents (eg. lopinavir/ritonavir, oseltamivir, favipiravir) for treatment of mild or severe COVID-19 |
Chemoprophylaxis in contacts, health care workers | ||
Reduction of progression to severe disease/ prevention of hospitalization in milder COVID-19 | ||
Methotrexate | 3 | Treatment of severe COVID-19 with methotrexate-containing nanoparticles |
Risk of COVID-19 in patients with rheumatic diseases on drugs like methotrexate | ||
Colchicine | 19 | Treatment of mild or severe COVID-19 |
Prevention of progression of mild COVID-19 to severe disease | ||
Treatment of myocardial injury in the context of COVID-19 |
COVID-19 coronavirus disease 19